Hi, all--
Because of all my A-Fib fun, my cardio has put me on Pradaxa 150 mg daily. I started today, and I felt nauseated for a couple hours. Hopefully that will pass once my body gets used to it. (The cardio took me off an aspirin regimen and replaced that now with the new drug).
Anyone else here on Pradaxa? Thoughts?
If this doesn't work for me...the next stop is coumadin (and I thought I was safe from coumadin when I had my valve repaired, not replaced!)
Thanks,
Debi
I hope it works well. I was just (a couple minutes ago) reading an article on the new "updated" guidelines for Afib, that might interest you
http://www.theheart.org/article/116...medium=email&utm_source=20101223_EN_Heartwire
"US societies bring atrial-fib guidelines almost up-to-date
December 23, 2010 | Steve Stiles"
..."The document from the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS), which updates guidelines published in 2006 [2], was released December 20, 2010 on the organizations' respective websites and will be published in their flagship journals. It follows publication of new AF guidelines from the Canadian Cardiovascular Society (CCS) in September and the European Society of Cardiology (ESC) in October, as reported by heartwire."...
They mention that they already will be updating then, hopefully in the beginning of the year, because of Pradaxa being approved.
"Now that the drug is approved, he said, they can go with plan B: since the dabigatran part has already been finalized, they will release an update to the update. "That is in the final process of being approved by all the boards of the ACC and AHA, and I believe will be out soon after the first of the year."
The dabigatran recommendations will be simple, according to Wann. Indications for oral anticoagulation in AF haven't changed, so "the way the guideline will read is that dabigatran substitutes for warfarin except in patients with valvular heart disease. Otherwise, obey the same rules that you'd obey for warfarin. If you'd start a patient on warfarin, you'd start them on dabigatran. The evidence that it prevents strokes at least as well as warfarin is quite convincing, and the updated guideline will reflect that."
Wann acknowledges that the availability of dabigatran steals some of the thunder from one of the new update's recommendations, that the combination of aspirin and clopidogrel (Plavix, Sanofi-Aventis/Bristol-Myers Squibb) "might be considered" to cut the risk of stroke and other vascular events as an alternative to warfarin (class IIb, level of evidence B).
Many patients with AF who might have gone with the double-antiplatelet therapy instead of warfarin now have the dabigatran option, he observed, so the importance of aspirin-clopidogrel "will pale in comparison with the impact that dabigatran will have on the oral anticoagulation scene."